Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Non-Age-Related Macular Degeneration

Purpose: to report the long-term results of intravitreal bevacizumab (avastin)therapy for choroidal neovascularization (cnv) secondary to non-age-related maculardegeneration (non-amd).methods: this prospective interventional case series was conducted on patients withnon-amd cnv. all patients received 1.25 mg intravitreal bevacizumab and werefollowed for at least 18 weeks. indications for retreatment were decreased visualacuity or recurrence of subretinal fluid or hemorrhage associated with leakage onfluorescein angiography. primary outcome measures were changes in best-correctedvisual acuity (bcva) and central macular thickness (cmt). secondary outcomemeasures consisted of any adverse event related to the therapy.results: the study included 31 eyes of 28 patients with non-amd cnv includingidiopathic (n=11), due to myopia (n=7), angioid streaks (n=5), and other disorders(n=8). mean initial bcva was 20/100 which improved to 20/60 at 6 weeks; 20/40 at12, 18, 24, and 36 weeks; and 20/30 at 54 weeks. serial optical coherence tomographymeasurements showed mean cmt of 288 ìm at baseline, which was decreased to 209ìm at last visit (p=0.95). there was no correlation between the underlying diseaseand changes in bcva during the follow-up period.conclusion: intravitreal bevacizumab significantly improved visual acuity in eyeswith non-amd cnv due to various etiologies.